The Devices Defining the New Generation of Trials
The category of connected clinical devices has expanded dramatically. What began with basic activity trackers has matured into a portfolio of medical-grade instruments capable of capturing continuous, regulatory-grade data streams. That includes:
- ECG Patches: Single-lead to 12-lead ambulatory patches worn for days or weeks. Key in cardiology, oncology (cardiac safety), and neurology studies. Devices like the Holter-class patches deliver continuous cardiac monitoring without clinic visits.
- Continuous Glucose Monitors (CGM): Critical in metabolic, diabetes, and GLP-1 trials. Interstitial glucose readings every few minutes replace dozens of fasting blood draws, reducing patient burden while generating far richer longitudinal datasets.
- Smart Inhalers: Bluetooth-connected inhalers record timestamp, dose, and inhaler technique for every actuation. Transforming adherence measurement in respiratory studies — from self-report to objective, real-time data.
- Biosensor Patches: Multi-parameter patches now capture temperature, respiration rate, SpO2, heart rate, and movement simultaneously. Used widely in oncology, infectious disease, and post-surgical monitoring studies.
- Medical-Grade Smartwatches: FDA-cleared wearables capturing validated actigraphy, heart rate variability, and sleep architecture. Especially valuable in CNS, rare disease, and immunology trials where fatigue and sleep are key endpoints.
- Electronic Injectors & Autoinjectors: Connected drug delivery devices verify injection site, time, and technique. Increasingly required in biologics and self-administered drug trials to confirm adherence and support PK/PD modelling.
In 2026, diagnostics extend beyond traditional clinical environments. Wearables and connected devices empower patients to generate clinically relevant data from home — what began as wellness tracking is becoming integral to clinical decision-making.
Why Decentralised Trials Depend on Device Logistics
Hybrid and fully decentralised clinical trials (DCTs) are no longer experimental — they are the default model for patient-centric research in 2026. Wearables and connected devices now support remote data capture across neurology, cardiology, and metabolic research, reducing site visit burden while capturing richer longitudinal data.
But this shift creates a new operational challenge: devices must be configured, shipped, tracked, and retrieved across multiple countries — often under different regulatory frameworks. A biosensor patch that collects data in Germany, the Netherlands, and the United States needs to meet the compliance requirements of all three jurisdictions simultaneously.
The Operational Reality
A multi-country Phase III study using connected devices across 40 sites may require hundreds of individual device units, each pre-configured, quality-checked, and shipped within a narrow activation window. When devices fail, replacements must arrive before the next assessment window closes. This is not a procurement challenge — it’s a clinical operations challenge.
From Data Capture to Regulatory Acquiescence
The ICH E6(R3) Good Clinical Practice guidelines — updated to reflect the realities of digital trials — explicitly recognise the use of wearable devices and their integration into study protocols. This regulatory endorsement has removed a major barrier to adoption, but it has also raised the bar for data quality.
Sponsors now need to demonstrate that the devices used in their studies are validated for the endpoints they support, that data flows are auditable from device to submission, and that any device failures or anomalies are documented and adjudicated. The device isn’t just a collection tool — it’s part of the regulatory evidence package.
Continuous monitoring also enables earlier detection of adverse events: from neutropenic fever signals in oncology patients to early atrial fibrillation detection in cardiac safety studies. This benefit is only realised if devices are functioning correctly and data is transmitted reliably throughout the trial — which requires active device management, not passive rental.
The Case for Global Equipment Rental
Most sponsors and CROs do not want to own clinical devices. The device landscape changes faster than procurement cycles. A CGM that is best-in-class for a diabetes trial starting today may be superseded before a longer-duration study completes. Ownership locks teams into specific hardware generations.
Global rental solves this. It provides access to the latest validated devices, configured for the specific study protocol, with logistics managed across every participating country. It also eliminates the capital expenditure of device ownership, the compliance overhead of managing a device inventory across jurisdictions, and the operational burden of handling returns, repairs, and replacements in-study.
At Clinichain, we provide connected devices and equipment rentals for global clinical studies — from single-site pilots to multi-country Phase III programmes. Every device leaves our facility configured, quality-checked, and ready to deploy. And when studies end, we manage the full return and reset cycle.
What We Offer
- Device selection guidance based on your endpoints
- Pre-configuration and quality control
- Global shipping and customs handling
- In-study replacement management
- End-of-study return logistics
The Device is Only as Good as its Deployment
The connected devices available to clinical researchers in 2026 are genuinely remarkable. They generate data that was impossible to capture just a decade ago. But the technology only delivers value if it reaches participants on time, functions correctly throughout the study window, and generates data that meets the evidentiary standards of a regulatory submission.
That’s the operational gap we exist to close. If you’re planning a study that depends on connected devices — whether you’re at protocol design stage or already in start-up — we’d welcome a conversation about what deployment looks like for your specific geography and endpoints.